GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiGen Biopharmaceuticals Holdings Ltd (ROCO:4157) » Definitions » Cyclically Adjusted Revenue per Share

TaiGen Biopharmaceuticals Holdings (ROCO:4157) Cyclically Adjusted Revenue per Share : NT$0.41 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is TaiGen Biopharmaceuticals Holdings Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

TaiGen Biopharmaceuticals Holdings's adjusted revenue per share for the three months ended in Dec. 2024 was NT$0.015. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$0.41 for the trailing ten years ended in Dec. 2024.

During the past 12 months, TaiGen Biopharmaceuticals Holdings's average Cyclically Adjusted Revenue Growth Rate was 2.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 2.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of TaiGen Biopharmaceuticals Holdings was 2.60% per year. The lowest was 2.60% per year. And the median was 2.60% per year.

As of today (2025-05-03), TaiGen Biopharmaceuticals Holdings's current stock price is NT$10.15. TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was NT$0.41. TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted PS Ratio of today is 24.76.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of TaiGen Biopharmaceuticals Holdings was 50.66. The lowest was 22.32. And the median was 38.32.


TaiGen Biopharmaceuticals Holdings Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiGen Biopharmaceuticals Holdings Cyclically Adjusted Revenue per Share Chart

TaiGen Biopharmaceuticals Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.38 0.38 0.40 0.41

TaiGen Biopharmaceuticals Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.40 0.41 0.41 0.41

Competitive Comparison of TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted PS Ratio falls into.


;
;

TaiGen Biopharmaceuticals Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TaiGen Biopharmaceuticals Holdings's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.015/133.1571*133.1571
=0.015

Current CPI (Dec. 2024) = 133.1571.

TaiGen Biopharmaceuticals Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 0.027 99.621 0.036
201506 0.030 100.684 0.040
201509 0.029 100.392 0.038
201512 0.027 99.792 0.036
201603 0.024 100.470 0.032
201606 0.071 101.688 0.093
201609 0.034 101.861 0.044
201612 0.077 101.863 0.101
201703 0.017 102.862 0.022
201706 0.739 103.349 0.952
201709 0.011 104.136 0.014
201712 0.004 104.011 0.005
201803 0.023 105.290 0.029
201806 0.005 106.317 0.006
201809 0.007 106.507 0.009
201812 0.007 105.998 0.009
201903 0.006 107.251 0.007
201906 0.005 108.070 0.006
201909 0.007 108.329 0.009
201912 0.010 108.420 0.012
202003 0.005 108.902 0.006
202006 0.010 108.767 0.012
202009 0.006 109.815 0.007
202012 0.011 109.897 0.013
202103 0.064 111.754 0.076
202106 1.730 114.631 2.010
202109 0.003 115.734 0.003
202112 0.002 117.630 0.002
202203 0.014 121.301 0.015
202206 0.004 125.017 0.004
202209 0.035 125.227 0.037
202212 0.007 125.222 0.007
202303 0.008 127.348 0.008
202306 0.139 128.729 0.144
202309 0.011 129.860 0.011
202312 0.012 129.419 0.012
202403 0.014 131.776 0.014
202406 0.170 132.554 0.171
202409 0.012 133.029 0.012
202412 0.015 133.157 0.015

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


TaiGen Biopharmaceuticals Holdings  (ROCO:4157) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=10.15/0.41
=24.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of TaiGen Biopharmaceuticals Holdings was 50.66. The lowest was 22.32. And the median was 38.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


TaiGen Biopharmaceuticals Holdings Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of TaiGen Biopharmaceuticals Holdings's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TaiGen Biopharmaceuticals Holdings Business Description

Traded in Other Exchanges
N/A
Address
No. 138 Xinming Road, 7th Floor, Neihu District, Taipei, TWN, 114
TaiGen Biopharmaceuticals Holdings Ltd is mainly engaged in the research and development of new drugs, including the selection of drug candidates, pre-IND trials and clinical trials. Its operating segment includes development, research and sales of new drugs, and other.

TaiGen Biopharmaceuticals Holdings Headlines

No Headlines